Lupin receives EIR for Aurangabad unit
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad facility.
The facility was under inspection by the USFDA between May 6, 2019 and May 15, 2019. The company's Aurangabad facility is involved in the manufacture of Oral Solid Dosage, Oral Liquid and Powder for Oral Suspension products for the US Market, WHO/Global Institution markets and the India market.
Lupin is an innovation-led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs, globally.
The shares of the company on Monday opened at Rs. 760 against Friday’s close of Rs. 767. At 15:43 hours, it was trading at Rs.755.20, 1.58 per cent lower than its previous close. The intraday high was Rs. 771.15 and intraday low was Rs. 741.10. Its 52-week high was Rs. 986 and 52-week low was Rs. 697.20 per share on the BSE.